0001072613-19-000106.txt : 20190214 0001072613-19-000106.hdr.sgml : 20190214 20190214151037 ACCESSION NUMBER: 0001072613-19-000106 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20190214 DATE AS OF CHANGE: 20190214 GROUP MEMBERS: ARCH VENTURE PARTNERS VIII, L.P. GROUP MEMBERS: ARCH VENTURE PARTNERS VIII, LLC GROUP MEMBERS: CLINTON BYBEE GROUP MEMBERS: KEITH CRANDELL GROUP MEMBERS: ROBERT NELSEN SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Kura Oncology, Inc. CENTRAL INDEX KEY: 0001422143 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 611547851 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-83933 FILM NUMBER: 19605156 BUSINESS ADDRESS: STREET 1: 3033 SCIENCE PARK ROAD, SUITE 220 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 500-8800 MAIL ADDRESS: STREET 1: 3033 SCIENCE PARK ROAD, SUITE 220 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: ZETA ACQUISITION CORP III DATE OF NAME CHANGE: 20071227 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ARCH Venture Fund VIII, L.P. CENTRAL INDEX KEY: 0001605598 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 8755 W. HIGGINS ROAD, SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 BUSINESS PHONE: 776-380-6600 MAIL ADDRESS: STREET 1: 8755 W. HIGGINS ROAD, SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 SC 13G/A 1 archviii-kura_13g18289.htm ARCH VENTURE FUND VIII, L.P. - KURA ONCOLOGY, INC. -- SCHEDULE 13G/A(#3)
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 3)*
 
 
 
 

Kura Oncology, Inc.
(Name of Issuer)
 
 
 
Common Stock par value $0.0001 per share
(Title of Class of Securities)
 
 
 
50127T109
(CUSIP Number)
 
 
 
December 31, 2018
(Date of Event Which Requires Filing of this Statement)
 
 
 
 
 
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)
☐ Rule 13d-1(c)
☒ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
 
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).
 
CUSIP No.   50127T109
13G
Page 2 of 6 Pages
 
 
 
 
Item 1(a). Name of Issuer

Kura Oncology, Inc. (the "Issuer").
 
 
Item 1(b). Address of Issuer's Principal Executive Offices

11119 N. Torrey Pines Road, Suite 125, La Jolla, CA  92037.
 

Item 2(a). Name of Person Filing

ARCH Venture Fund VIII, L.P. ("ARCH Venture Fund VIII"); ARCH Venture Partners VIII, L.P. ("AVP VIII LP"); ARCH Venture Partners VIII, LLC ("AVP VIII LLC") (collectively, the "Reporting Entities" and individually, each a "Reporting Entity"); and Keith Crandell ("Crandell"), Robert Nelsen ("Nelsen") and Clinton Bybee ("Bybee") (collectively, the "Managing Directors" and individually, each a "Managing Director").  The Reporting Entities and the Managing Directors collectively are referred to as the "Reporting Persons".
 

Item 2(b). Address of Principal Business Office or, if none, Residence

8755 W. Higgins Avenue, Suite 1025, Chicago, IL 60631
 

Item 2(c). Citizenship

ARCH Venture Fund VIII and AVP VIII LP are limited partnerships organized under the laws of the State of Delaware. AVP VIII LLC is a limited liability company organized under the laws of the State of Delaware.  Each Managing Director is a US citizen.
 

Item 2(d). Title of Class of Securities

Common stock, par value $0.0001 per share.
 
 
Item 2(e). CUSIP Number

50127T109
 

Item 3.
If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
 
Not Applicable.
 
 
Item 4. Ownership
 
Not Applicable.
 
 
Item 5. Ownership of Five Percent or Less of a Class

Each of the Reporting Persons has ceased to beneficially own five percent (5%) or more of the Issuer's outstanding Common Stock.
 

Item 6. Ownership of More Than Five Percent on Behalf of Another Person

Not Applicable.

 
 
CUSIP No.   50127T109
13G
Page 3 of 6 Pages
 
 
 
 
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not Applicable.
 

Item 8. Identification and Classification of Members of the Group

Not Applicable.
 

Item 9. Notice of Dissolution of Group

Not Applicable.
 
 
Item 10.
Certification
 
Not Applicable.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

CUSIP No.   50127T109
13G
Page 4 of 6 Pages
 
 
SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated:            February 14, 2019
 
 
ARCH VENTURE FUND VIII, L.P.
 
 
By:   ARCH Venture Partners VIII, L.P.
           its General Partner
 
 
 By:   ARCH Venture Partners VIII, LLC
 
                  its General Partner
 
 
  By:                   *                                         
            
                          Keith Crandell
 
                          Managing Director
 
 
 
ARCH VENTURE PARTNERS VIII, L.P.
 
 
By:   ARCH Venture Partners VIII, LLC
           its General Partner
 
 
 By:                    *                                         
 
                  Keith Crandell
                    Managing Director
 
 
 
ARCH VENTURE PARTNERS VIII, LLC
 
 
By:                       *                                         
           Keith Crandell
           Managing Director
 
 
 
                             *                                         
  Keith Crandell
 
 
                             *                                         
 
Robert Nelsen
 
 
                             *                                         
 
Clinton Bybee
 
 
 
     
* By:  /s/ Mark McDonnell                            
   
           Mark McDonnell as
   
          Attorney-in-Fact
    
 
This Amendment No. 3 to Schedule 13G was executed by Mark McDonnell pursuant to Powers of Attorney attached hereto as Exhibit 2 and incorporated herein by reference.
 
CUSIP No.   50127T109
13G
Page 5 of 6 Pages
 
Exhibit 1

AGREEMENT

Pursuant to Rule 13d-1-(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of stock of Kura Oncology, Inc.
 
This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.
 
 
Dated:    February 14, 2019
ARCH VENTURE FUND VIII, L.P.
 
 
By:   ARCH Venture Partners VIII, L.P.
           its General Partner
 
 
 By:   ARCH Venture Partners VIII, LLC
 
                  its General Partner
 
 
  By:                   *                                         
            
                          Keith Crandell
 
                          Managing Director
 
 
 
ARCH VENTURE PARTNERS VIII, L.P.
 
 
By:   ARCH Venture Partners VIII, LLC
           its General Partner
 
 
 By:                    *                                         
 
                  Keith Crandell
                    Managing Director
 
 
 
ARCH VENTURE PARTNERS VIII, LLC
 
 
By:                       *                                         
           Keith Crandell
           Managing Director
 
 
 
                             *                                         
  Keith Crandell
 
 
                             *                                         
 
Robert Nelsen
 
 
                             *                                         
 
Clinton Bybee
 
 
 
     
* By:  /s/ Mark McDonnell                            
   
           Mark McDonnell as
   
          Attorney-in-Fact
    
 
 
This Agreement was executed by Mark McDonnell pursuant to Powers of Attorney attached hereto as Exhibit 2 and incorporated herein by reference.
CUSIP No.   50127T109
13G
Page 6 of 6 Pages
 
Exhibit 2

POWERS OF ATTORNEY
 
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark McDonnell his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a direct or indirect general partner, member, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his substitutes, may lawfully do or cause to be done by virtue hereof. This Power of Attorney shall remain in full force and effect with respect to each undersigned person unless and until six months after such person is both no longer a Managing Director of ARCH Venture Partners and no longer serving on the board of directors of any portfolio company of any ARCH Venture Partners fund.

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 9th day of March, 2015.
 
 
 
ARCH VENTURE FUND VIII, L.P.
 
 
By:   ARCH Venture Partners VIII, L.P.
           its General Partner
 
 
 By:   ARCH Venture Partners VIII, LLC
 
                  its General Partner
 
 
  By:  /s/ Keith Crandell                                
 
                          Managing Director
 
 
 
ARCH VENTURE PARTNERS VIII, L.P.
 
 
By:   ARCH Venture Partners VIII, LLC
           its General Partner
 
 
 By:   /s/ Keith Crandell                                
                    Managing Director
 
 
 
ARCH VENTURE PARTNERS VIII, LLC
 
 
By:   /s/ Keith Crandell                                
           Managing Director
 
 
 
/s/ Keith Crandell                                        
  Keith Crandell
 
 
/s/ Robert Nelsen                                        
 
Robert Nelsen
 
 
/s/ Clinton Bybee                                        
 
Clinton Bybee
 
 
/s/ Kristina Burow                                       
 
Kristina Burow
 
 
/s/ Paul Thurk                                              
 
Paul Thurk